T he recent launch of multiple major US cancer initiatives has infused cash into immunotherapy, one of the most promising new methods of cancer treatment. But researchers warn that the money may be wasted without concrete plans to coordinate the programmes. "There's a lack of overt leadership, and in the absence of a logical strategy we have a tendency to throw plates of spaghetti against the wall and hope it sticks, " says Ira Mellman, vice-president of cancer immunology at the biotechnology company Genentech in South San Francisco, California.
The broadest programme is the US government's National Cancer Moonshot, which hopes to receive US$1 billion by next year for 8 areas of cancer research. Immunotherapy, which recalibrates the body's own immune defence against cancer, is among them. It "is poised to be a critical part of our nation's anticancer strategy", the project's leader, US vice-president Joe Biden, said last week at the annual meeting of the American Association for Cancer Research (AACR) in New Orleans, Louisiana.
An advisory panel will release more-detailed plans for the government programme in June. Meanwhile, three privately funded immunotherapy research projects are gearing up: the $250-million Parker Institute for Cancer Immunotherapy, funded by Sean Parker, co-founder of the music-file-sharing company Napster, and announced on 13 April; a $125-million Immunotherapy Center at Johns Hopkins University in Baltimore, Maryland, unveiled in March; and the Cancer MoonShot 2020 Program, announced in January by biotechnology billionaire Patrick Soon-Shiong.
This sudden proliferation of cancer initiatives is reminiscent of the spate of brainresearch projects launched in the past few years -some of which have foundered through poor leadership. Europe's Human Brain Project, for instance, almost ran aground after a series of top-down decisions alienated the neuroscience community. By contrast, the US BRAIN Initiative set priorities after consulting with neuroscientists, and awarded grants through a conventional peer-reviewed process, ensuring community acceptance. Now cancer researchers are left wondering how their moonshots will proceed. At the AACR meeting, Biden said that he had met representatives of many cancer-funding projects. "Why is all of that being done separately?" he asked scientists in the audience, noting that progress is accelerated by collaboration.
The privately funded initiatives are more concerned with meeting their own goals -and satisfying their funders -than with coordinating efforts in the field. "I don't see my role as trying to answer this larger question about how does this all fit together, " says Jeffrey Bluestone, chief executive of the Parker Institute. "I'm focused on how to make sure what we do is impactful for patients. "
But Douglas Lowy, acting director of the US National Cancer Institute (NCI), which is coordinating the government moonshot, notes an overlap with the leadership of the various projects. Many researchers are looking to the Biden project to make a big investment in basic cancer immunology and to address broader barriers to research, such as data hoarding. Gotwals, for instance, notes that the results of industry-sponsored clinical trials now under way could help other companies to decide which approaches to test, but that results are typically not made public until 9-12 months after a trial ends. Companies are reluctant to share data before then, both to comply with regulatory requirements and to protect their intellectual property. "It's not trivial to figure out how to make that work, " Gotwals says.
Biden seems to be hearing that message. At the AACR meeting, he said that data sharing often comes up when he speaks to scientists about the moonshot. Lowy says that the NCI is already planning to open a Genomic Data Commons in June to host detailed information on cancer patients. Sharing data collected in company-sponsored clinical trials is trickier because patients must give informed consent.
In the meantime, the government moonshot faces a major hurdle: its funding is at the mercy of legislators who may be loath to give US President Barack Obama a victory in his last year in office. "It will be very difficult for us to initiate all of the programmes that we're looking forward to the blue-ribbon panel recommending if there isn't funding, " Lowy says. ■ SEE EDITORIAL P.414
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BY H E I D I L E D F O R D
I t is precision medicine taken to the extreme: cancer-fighting vaccines that are custom designed for patients according to the mutations in their individual tumours. With early clinical trials showing promise, that extreme could one day become commonplace -but only if drug developers can scale up and speed up the production of their tailored medicines.
The topic was front and centre at the American Association for Cancer Research (AACR) annual meeting in New Orleans, Louisiana, on 16-20 April. Researchers described early data from clinical trials that suggested that personalized vaccines can trigger immune responses against cancer cells. Investors seem optimistic that those results will translate into benefits for patients; over the past year, they have pumped cash into biotechnology start-up companies that are pursuing the approach.
But some researchers worry that the excitement is too much, too soon for an approach that still faces many technical challenges. "What I do really puzzle at is the level of what I would call irrational exuberance, " says Drew Pardoll, a cancer immunologist at Johns Hopkins University in Baltimore, Maryland.
The concept of a vaccine to treat cancer has intrinsic appeal. Some tumour proteins are either mutated or expressed at different levels than in normal tissue. This suggests that the immune system could recognize these unusual proteins as foreign if it were alerted to their presence by a vaccine containing fragments of the mutant protein. The immune system's army of T cells could then seek out and destroy cancer cells that bear the protein.
Decades of research into cancer-treatment vaccines have thus far yielded disappointing clinical-trial results, but advances in recent years -including a suite of drugs that might amplify the effects of cancer vaccines -have rekindled hope for the field. And DNA sequencing of tumour genomes has revealed a staggering diversity of mutations that produce proteins that could serve as 'antigens' -molecules that alert the immune system to the tumour's presence.
Last year, researchers reported that they had triggered immune responses in three people with melanoma by administering a vaccine tailored to their potential tumour antigens (B. M. Carreno et al. Science 348, 803-808; 2015) . The vaccines' effects on tumour growth are not yet clear, but by the end of 2015, several companies had announced their intention to enter the field. Gritstone Oncology, a start-up firm in Emeryville, California, raised US$102 million to pursue the approach, and Neon Therapeutics of Cambridge, Massachusetts, raised $55 million. A third company, Caperna, was spun out of the prominent biotechnology company Moderna Therapeutics, also in Cambridge.
VACCINE HURDLES
Academic groups are also moving quickly. At the AACR meeting, immunologist Robert Schreiber of Washington University in St. Louis, Missouri, described six ongoing studies at his institution, in cancers ranging from melanoma to pancreatic. And Catherine Wu of the Dana-Farber Cancer Institute in Boston, Massachusetts, presented data showing signs of T-cell responses to a melanoma vaccine. But it takes Wu's team about 12 weeks to generate a vaccine, and the Washington University team needs about 8 weeks. That could limit the treatment to slow-growing cancers, says Wu.
There is also a reason that so many researchers choose melanoma for proof-of-principle trials. Melanoma tumours tend to harbour many mutations, which provide scientists with ample opportunity to select those that may serve as antigens. Some researchers worry that tumours with fewer mutations may not be so suitable for personalized vaccines.
Pardoll, meanwhile, is concerned that the field is shifting too quickly, leaving behind decades of research on antigens that might be shared across tumours -work that has not borne out in clinical trials thus far, but would be much simpler to manufacture and deploy on a large scale. "I will be the happiest person in the world to be proven wrong on these, " he says of personalized vaccines. "But I think one has to nonetheless be cognizant of where the challenges are. 
